ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1782

Mycophenolic Acid Decreases IL-10 and IL-6 Production By B Cells of Granulomatosis with Polyangiitis Patients and Healthy Controls in Vitro

Anouk von Borstel1, Wayel H. Abdulahad2, Abraham Rutgers2, Judith Land2, Coen A. Stegeman1, Peter Heeringa3 and Jan-Stephan F. Sanders1, 1Internal Medicine, Division of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, 2Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, 3Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: azathioprine, B cells, cytokines, mycophenolate mofetil and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Vasculitis Poster II: ANCA-Associated Vasculitis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Granulomatosis with polyangiitis (GPA) is a relapsing autoimmune disease affecting small- to medium-sized blood vessels. B cells are thought to play an important antibody-independent role in GPA patients. Immunosuppressants are used to induce remission at initial onset of disease, and subsequently used as maintenance treatment. Mycophenolate mofetil (MMF) was found to be effective for both induction and maintenance of remission in GPA; although, azathioprine (AZA) is superior as maintenance therapy compared to MMF. Little is known about the effect of these commonly used drugs on B cell cytokine production. We hypothesized that the differences in the efficacy of MMF and AZA could be the result of differential effects on B cell cytokine production. Therefore, we studied the effects of MMF and AZA on in vitro B cell cytokine production.


Methods:

We assessed the in vitro effect of the active compounds of MMF (MPA) and AZA (6-MP) on B cell cytokine production. PBMCs of twenty untreated GPA patients in remission and twenty age- and sex-matched healthy controls (HCs) were isolated. PBMCs were cultured with CpG and 3 uM MPA or 6-MP. After 3 days, PBMCs were restimulated with Ca-I and PMA for 5h in the presence of BFA, stained for intracellular IL-6 and IL-10 and measured by flow cytometry. In addition, to determine whether in vivo use of MMF or AZA influences in vitro B cell cytokine production, PBMCs from 14 patients in stable remission were cultured and stimulated as mentioned above. From each patient two samples were analyzed, one when patients were not treated and one when patients were receiving either MMF (n=4) or AZA (n=10). For comparison, PBMCs from 14 matched HCs were analyzed simultaneously.


Results:

MPA significantly decreased the frequency of IL-10+ and IL-6+ B cells in HCs and GPA patients, compared to CpG alone (p<0.001) and CpG+6-MP (p<0.001). PBMCs from GPA patients that were actively treated with MMF or AZA, tended to have a reduced IL-10+ B cell frequency compared to PBMCs from the same donors that did not receive treatment (p=0.1) or healthy controls (p=0.09). This reduction in IL-10+ B cells was only seen in MMF- and not in AZA-treated patients (p=0.09). In contrast, no effect of MMF or AZA was found on IL-6+ B cells (%).

Conclusion:

The decrease in in vitro B cell cytokine production in the presence of mycophenolic acid might explain why this agent is less effective as maintenance therapy in GPA. Further research is needed to elucidate whether this in vitro finding is clinically relevant.


Disclosure: A. von Borstel, None; W. H. Abdulahad, None; A. Rutgers, None; J. Land, None; C. A. Stegeman, None; P. Heeringa, None; J. S. F. Sanders, Dutch Kidney Foundation, 2,Netherlands Organization for Scientific Research, 2.

To cite this abstract in AMA style:

von Borstel A, Abdulahad WH, Rutgers A, Land J, Stegeman CA, Heeringa P, Sanders JSF. Mycophenolic Acid Decreases IL-10 and IL-6 Production By B Cells of Granulomatosis with Polyangiitis Patients and Healthy Controls in Vitro [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/mycophenolic-acid-decreases-il-10-and-il-6-production-by-b-cells-of-granulomatosis-with-polyangiitis-patients-and-healthy-controls-in-vitro/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mycophenolic-acid-decreases-il-10-and-il-6-production-by-b-cells-of-granulomatosis-with-polyangiitis-patients-and-healthy-controls-in-vitro/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology